Sangamo Therapeutics, Inc.

Equities

SGMO

US8006771062

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
0.5614 ^USD	+7.26%		+1.01%	+3.33%

05-09	Transcript : Sangamo Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
05-09	Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000	MT

Sangamo Therapeutics to Present at the Jefferies Cell and Genetic Medicine Summit

September 21, 2023 at 01:28 pm

BRISBANE - Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that it will participate in the Jefferies Cell & Genetic Medicine Summit, to be held from September 26-27, 2023 in New York City.

Sandy Macrae, Sangamo's President and Chief Executive Officer is scheduled to present on Wednesday, September 27th at 11:00AM ET. A live webcast of the presentation will be available here and on the Company's Investor Events webpage. A replay of the presentation will be available on the Sangamo Therapeutics website for 90 days after the event.

About Sangamo Therapeutics

Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don't exist.

Contact:

Louise Wilkie

Email: ir@sangamo.com

Latest news about Sangamo Therapeutics, Inc.

Transcript : Sangamo Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000	05-09	MT
Sangamo Therapeutics, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2024	05-09	CI
Sangamo Therapeutics Prices $24 Million Registered Direct Offering	03-22	MT
Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says	03-14	MT
Transcript : Sangamo Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024	03-13
Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023	03-13	CI
Sangamo Therapeutics Announces Data from Novel Proprietary Neurotropic Aav Capsid Demonstrating Industry-Leading Blood-Brain Barrier Penetration and Brain Transduction in Nhps	03-13	CI
Sangamo Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-13	CI
Sangamo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-13	CI
Sangamo Therapeutics Says Early Phase 1/2 Data Shows 'Durable' Safety, Efficacy of Fabry Disease Drug Candidate	02-06	MT
Sangamo Therapeutics, Inc. Announces Updated Preliminary Data from the Phase 1/2 STAAR Clinical Study Evaluating Isaralgagene Civaparvovec, or ST-920	02-04	CI
Vaxcyte Names Chief People Officer	01-16	MT
Sangamo Therapeutics, Inc.(NasdaqGS:SGMO) dropped from NASDAQ Biotechnology Index	12-15	CI
Sangamo Therapeutics, Inc Announces Pivotal Readout in the Middle of 2024 for the Phase 3 Affine Trial	12-13	CI
North American Morning Briefing : Stock Futures -2-	11-08	DJ
Truist Securities Downgrades Sangamo Therapeutics to Hold From Buy	11-07	MT
North American Morning Briefing : Higher Bond -2-	11-07	DJ
HC Wainwright Cuts Price Target on Sangamo Therapeutics to $3 From $5, Maintains Buy Rating	11-06	MT
Wells Fargo Downgrades Sangamo Therapeutics to Equal-Weight From Overweight, Price Target is $1	11-06	MT
North American Morning Briefing : Stocks Look to -2-	11-06	DJ
Wedbush Lowers Sangamo Therapeutics' PT to $2 From $10 as Result of Valuing Potential Royalty From ST-920 Sales, Keeps Outperform Rating	11-03	MT
RBC Downgrades Sangamo Therapeutics to Sector Perform From Outperform, Cuts Price Target to $2 From $6, Cites 'Cash Preservation Mode,' Keeps Speculative Risk	11-03	MT
Transcript : Sangamo Therapeutics, Inc., Q3 2023 Earnings Call, Nov 02, 2023	11-02
Sangamo Therapeutics, Inc. Reports Impairment Charges for the Three Months Ended September 30, 2023	11-01	CI

Chart Sangamo Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.

Sector

Biotechnology & Medical Research

Calendar

13/05/2024 - RBC Capital Markets Global Healthcare Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Sangamo Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.5614 USD

Average target price

3.5 USD

Spread / Average Target

+523.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SANGAMO THERAPEUTICS, INC.	+3.33%	116M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs